CONNECT WITH US:
Asia-Pacific has Record Year for Clinical Trials according to Novotech
SAN FRANCISCO, CA, 2020年01月14日 - (JCN Newswire) - Novotech, the largest biotech CRO in Asia Pacific, says the region has had a record year by number of studies, experienced world-class sites and investigators, and patient enrollment.
Novotech released its 'Asia-Pacific Industry Highlights 2019-2020' during the JP Morgan Healthcare Conference in San Francisco as part of its Biotech Industry Briefing session on the benefits of conducting research in Asia-Pacific.
The Biotech Industry Briefing covered:
- Asia's vast patient pools,
- High-quality infrastructure,
- Lower trial concentration,
- Comparable quality and lower costs,
- Key destination for biotech companies for later phase trials.
Novotech also spoke about the benefits of running trials with regional CRO partners in the context of multi-region trials.
Novotech CRO's Dr John Moller said "Asia-Pacific is now recognised by clinical phase biotech companies for accelerated patient enrollment - especially in rare diseases, metabolic conditions, oncology, immuno-oncology and infectious diseases - and lower clinical research costs, with some of the most experienced investigators and research teams.
"Biotech clinical research has been increasing globally by 10% per year, but in the APAC region this increase has been over 25% per year. This follows news from Australia that most clinical phase biotechs would be eligible for a 40%+ cash rebate on clinical research spend, preserved as an incentive for conducting clinical research in Australia.
"We have seen small to mid-size biotechs increasingly looking to partner with CROs of a similar size and mindset. We also found the region focused on more efficient registration and approval processes with significant improvements introduced in China and South Korea in 2019. We are ensuring our clients understand these changes which can save them valuable time and funds.
"Novotech has been expanding to meet growing demand, increasing staff by +20% in 2019, and announcing a strategic partnership with PPC Group. The partnership creates the largest biotech specialist CRO group in the Asia-Pacific, bringing together approximately 1,200 staff with significant scale and synergies across countries, research institutions, trial phases, therapeutic areas and functional specialities."
Novotech clients also have access to more than 350 clinical and operations staff across 28 cities in mainland China.
About Novotech -
Novotech, the Frost & Sullivan Asia-Pacific Biotech CRO of the Year the past 5 years, is internationally recognized as the leading Asia-Pacific full-service CRO. Established more than 20 years ago, Novotech now has 13 offices across 11 countries in APAC, and has been instrumental in the success of hundreds of Phase I-IV clinical trials in the region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, safety services, central lab services, report write-up to ICH requirements, project and vendor management.
About PPC -
PPC Group, a full-service CRO founded in 1997, offers clinical research services, laboratory and site management. PPC Group has over 600 employees, with headquarters in Shanghai and 11 offices across China, Taiwan, Japan and South Korea. PPC manages 4 Phase I Clinical Pharmacology Units, 3 Bioanalytical Labs, and a Central Laboratory.
PPC has supported more than 350 customers, performing over 500 Phase I-IV clinical trials and over 1500 generic drug bioequivalence studies. PPC is the first CRO in Asia to have undergone inspections by all major international regulatory agencies (US FDA, EU EMA, Japan's PMDA and China's NMPA), each resulting in successful client product registration.
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Showa Denko Announces Merger between Consolidated Subsidiaries and Change of Company Name
Sep 24, 2020 19:00 JST
Fujitsu and SNP Announce Global Platinum Partnership Agreement -- Accelerating SAP S/4HANA Conversion Business with Advanced Data Transformation Technologies
Sep 24, 2020 14:55 JST
Hitachi ABB Power Grids to Invest Over $100 Million in Strategic Realignment of Global High-Voltage Switchgear Business
Sep 24, 2020 13:30 JST
Mitsubishi Corporation: Use of CO2 in Concrete / Partnership with Blue Planet Systems Corporation
Sep 23, 2020 16:00 JST
Hitachi Hosts "Hitachi Social Innovation Forum 2020 TOKYO ONLINE"
Sep 23, 2020 14:22 JST
Hitachi ABB Power Grids Launches Open and Scalable Ecosystem for Digitalization of Transformers
Sep 23, 2020 10:38 JST
Fujitsu to Deliver New Supercomputer System for Canon
Sep 23, 2020 10:25 JST
Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients
Sep 23, 2020 09:24 JST
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 23, 2020 09:10 JST
Toyota Motor Corporation Announces Appointment of Tommi Makinen as a Motorsport Advisor
Sep 22, 2020 18:08 JST
Evans Claims Victory for TOYOTA GAZOO Racing on a Turbulent Final Day
Sep 21, 2020 10:48 JST
GR Super Sport Makes Dynamic Public Debut at Le Mans
Sep 21, 2020 10:24 JST
Toyota Gazoo Racing Takes Le Mans Hat-Trick
Sep 21, 2020 10:11 JST
MITSUBISHI MOTORS Redesigns New ECLIPSE CROSS, Also Offered with Plug-in Hybrid Powertrain
Sep 18, 2020 12:09 JST
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sep 18, 2020 11:29 JST
Fujitsu Develops Technology to Block Facial Authentication Fraud
Sep 18, 2020 10:20 JST
New Report from Hitachi ABB Power Grids Confirms North America's Sustainable Energy Future
Sep 17, 2020 16:48 JST
TRI-AD Office Wins "Creative Office Award" at 33rd Nikkei New Office Awards
Sep 17, 2020 15:36 JST
Denyo and Toyota Jointly Develop and Start Verification Tests for Fuel Cell Power Supply Vehicle that Uses Hydrogen to Generate Electricity
Sep 17, 2020 13:40 JST
Eisai Establishes Pharma Sales Subsidiary in Vietnam
Sep 17, 2020 09:59 JST
More Latest Release >>